Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Survey Rate of Generic Drug Use Under High-Cost Healthcare System; Regulatory Reform Council Concerned that System Provides Little Incentive to Use Generics
August 6, 2014
- PFSB’s Budget Request for FY2015 Will Seek Funding to Strengthen Operations at PMDA: Director-General
August 6, 2014
- MHLW to Remind Drug Makers of Proper ADR Reporting in Wake of Administrative Improvement Order to Novartis
August 4, 2014
- MHLW to Fund Research Aimed at Obtaining Additional Indications for Intractable and Orphan Diseases for Existing Drugs
August 4, 2014
- PAFSC First Committee Backs Approval of MSD’s Insomnia Treatment
August 4, 2014
- JPMA to Examine Clinical Trial Costs
August 1, 2014
- Improvement Order Issued to Novartis over Delayed ADR Reporting
August 1, 2014
- Government to Increase Review Fee for New Generic Drugs from 630,000 Yen to 940,000 Yen
August 1, 2014
- JPA’s Abe Makes Chuikyo Debut, Says No to Annual Drug Price Revisions
July 31, 2014
- Regulatory Review Trend in Japan Signals Pharmas’ Shift to Cancer Drugs: Jiho Tally
July 30, 2014
- MHLW Bulletin Notifies of Revised Package Inserts Warning Concurrent Use of ARBs, ACE Inhibitors
July 30, 2014
- NIBIO Initiates Support for Applied Research on 15 Promising Drug Seeds with Goal of First Licensing Agreement by FY2015
July 30, 2014
- MHLW to Review Criteria for Clinical Research Core Hospitals by April
July 29, 2014
- Revised PAL Mandating Submission of Package Inserts to Minister Will Take Effect on Nov 25
July 29, 2014
- Govt Thought TPP Talks Would Be Wrapped Up Sooner: Official
July 29, 2014
- PAFSC’s Second Committee to Discuss Kyowa Kirin’s Long-Acting G-CSF Drug Pegfilgrastim on August 8
July 29, 2014
- Editor’s Pick: Five Healthcare News Headlines for July14 - July 25
July 28, 2014
- Health Minister Calls for Strict Compliance with Transparency Guidelines
July 28, 2014
- Japan OKs Guidelines for FY2015 Budget Requests, Natural Rise of 830 Billion Yen in Social Security Costs
July 28, 2014
- PDMA to Issue Practical Notification on Submission of Electronic Applications for Approval Next January at Earliest
July 28, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…